]>
IRCT20171213037866N2 IRCT 2020-05-07 Semnan University of Medical Sciences Evaluation of the effect of jujube product on Covid-19 patients Efficacy of jujube product in accelerating the recovery process of Covid -19 patients 2020-05-09 anticipated 68 Complete https://irct.ir/trial/47684 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block Randomization Using four blocks, we randomly arrange the patients using the rand section of the software and enter the study. The patient code table is provided to the analyst and will be used for analysis after the study, Blinding description: In this study, the analyst and the recipient of the drug do not know how to allocate intervention and treatment groups. After accidentally entering the study, patients receive medication based on the received code and are unaware of the type of treatment. 3 COVID-19. Intervention 1: Intervention group: In addition to the treatment protocol, patients receive 7 cc of jujube twice a day, 7 cc each. Intervention 2: Control group: The treatment is done according to the protocol and is only for comparison with the intervention group. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No further information is available
public نسیم بهنود
Semnan - Semnan: 17 Shahrivar Blvd., South Side of the School of Dentistry, Specialized and Subspecialty Polyclinic No. 2 - Health Center of Traditional Medicine Semnan University of Medical Sciences
Semnan Iran (Islamic Republic of) 9443135187 +98 23 3333 4623 dr.nbehnoud@gmail.com Semnan University of Medical Sciences scientific Ali Gohari
Semnan Basij Boulevard Headquarters of Semnan University of Medical Sciences and Health Services
Semnan Iran (Islamic Republic of) 3518794431 +98 23 3344 1022 aligohari@semums.ac.ir Semnan University of Medical Sciences Iran (Islamic Republic of) The patient does not suffer from any serious concomitant diseases of the pulmonary, cerebral, and endocrine glands The patient's ability and personal desire to fill out a personal consent form to enter the study The patient has not been intubated 18 years 75 years Both Pregnancy and lactation Existence of any history of allergies to jujube and its products The patient's inability to take oral form There are any conditions in the patient that, according to the doctor's judgment, prevent the continuation of medical intervention. Concomitant use of corticosteroids, immunoglobulin or interferon Patient intubation Nausea and vomiting and oral intolerance Treatment-resistant hypoxemia Loss of consciousness Hemodynamic instability Hypercapnia - Respiratory fatigue Existence of any known side effects of consuming any of the components of jujube product B34.2 Coronavirus infection, unspecified Treatment - Drugs Treatment - Drugs Intervention group: In addition to the treatment protocol, patients receive 7 cc of jujube twice a day, 7 cc each. Control group: The treatment is done according to the protocol and is only for comparison with the intervention group. Clinical symptoms (Coronavirus infection). Timepoint: Before starting the study and daily until discharge. Method of measurement: Laboratory values and radiographic changes or CT scans and questionnaire. Semnan University of Medical Sciences Approved 2020-05-03 Ethics committee of Semnan University of Medical Sciences Semnan University of Medical Sciences, Basij Blvd, Semnan Semnan Semnan Iran (Islamic Republic of)